Views & Analysis Genetic testing hopes to speed up drug development in rare e... When it comes to fighting rare diseases, the biggest barrier to overcome is often the lack of knowledge around the condition.
News Karyopharm eyes Xpovio filing in myelofibrosis on mixed data Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.